1.Influence of erythropoietin therapy with oral iron supplementation on red blood cell distribution width in chronic heart failure patients with anemia
Chinese Journal of Primary Medicine and Pharmacy 2015;(18):2777-2780
Objective To analyze the effect of erythropoietin therapy with oral iron supplementation on red blood cell distribution width (RDW)in chronic heart failure patients with anemia.Methods 148 patients of chronic heart failure with anemia from September 2014 to March 2015 in our hospital were included and randomly divided into two groups with the random number table,with 74 cases in each group.The control group were treated with convention-al anti heart failure therapy,the treatment group were treated with erythropoietin and oral iron supplementation on the basis of routine treatment for four weeks.RDW was tested by automatic five classification blood analyzer.The correla-tion between RDW and other detection indexes was analyzed.Results The levels of RDW in the treatment group were significantly lower than those of the control group[(13.08 ±0.792)vs (14.32 ±0.864),t =-8.974,P <0.01].Before treatment,bivariate analysis in the treatment group showed that RDW had positive correlation with NT-proBNP and high -sensitivity C -relative protein (hs -CRP)(r =0.783,P <0.01;r =0.870,P <0.01),but negative correlation with serum creatinine (Cr)and hemoglobin (r =-0.338,P <0.01;r =-0.743,P <0.01).Af-ter treatment,bivariate correlations analysis in the treatment group showed that the difference of RDW was positive correlation with the difference of NT -proBNP,high -sensitivity C -relative protein (hs -CRP)(r =0.783,P <0.01;r =0.680,P <0.01),but negative correlation with the difference of hemoglobin(r =-0.459,P <0.01),and no correlation with the others (Cr,UA,LDL,TC,TG and LVEF).Conclusion On the basis of conventional anti heart failure treatment,erythropoietin therapy with oral iron supplementation against anemia could improve heart func-tion of CHF and decrease the levels of RDW.RDW may be served as one of observing indexes of the worsening and effect judgment in chronic heart failure patients with anemia.
2.Research progress of primary extramedullary plasmacytoma
Journal of International Oncology 2016;43(2):138-140
Extramedullary plasmacytoma (EMP) is a rare tumor characterized by proliferation of monoclonal plasma cells,often occurs in the head and neck,followed by gastrointestinal and skin.Diagnosis is based on biopsy,which is the only accurate and reliable method.EMP is needed to discriminate with similar diseases.Radiotherapy is the preferred treatment method of EMP,because it has a higher radiation sensitivity.Sometime we can choose comprehensive treatment because of illness need.Hematopoietic stem cell transplantation is not as the preferred treatment option because of transplant rejection.
3.The progress of low-dose chemotherapy in neuroblastoma
International Journal of Pediatrics 2012;39(3):301-303
Low-dose chemotherapy is concerned in treating malignant tumor in recent years.The lowdose,metronomic chemotherapy is not only effective in antiangiogenic,but also avoid chemotherapy side effects,such as suppression of bone marrow,dysfunction of liver and kidney,gastrointestinal reaction and drug resistance.Thereby it can increase patient compliance,improve life quality and prolong survival time.Currently chemotherapy in neuroblastoma still plays a key role,especially low-dose chemotherapy,which can protect self-immune function and reduce the physical injury in children.
Result Analysis
Print
Save
E-mail